-
Apogee Therapeutics NasdaqGM:APGE Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Location: Building 17, Waltham, MA, 02453, United States | Website: https://www.apogeetherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.867B
Cash
513.3M
Avg Qtr Burn
-47.0M
Short % of Float
26.23%
Insider Ownership
7.63%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2 Data readout | ||
APG777 Details Asthma | Phase 2 Initiation | |
APG808 Details Allergic diseases Type 2, Chronic obstructive pulmonary disease, Asthma | Phase 1b Update | |
APG279 (APG777 + APG990) Details Atopic Dermatitis (AD) | Phase 1b Initiation | |
APG990 Details Atopic dermatitis | Phase 1 Data readout | |
APG333 Details Asthma, Chronic obstructive pulmonary disease | Phase 1 Data readout |